All companies › ELV

ELV · Elevance Health, Inc.

Everything on this page is public record — SEC Form 4 filings and congressional disclosures — alongside any INSIDER SCANNER research case for this company.

Open-market buys0
Open-market sells13
Research cases0
Last filing2026-10-22

Insider flow: Selling only — a count of disclosed transactions, not a rating or a recommendation.

Insider transaction timeline

Every reported transaction, positioned by trade date. Purchases sit above the axis, sales below; circle area is proportional to dollar value. No share-price line is drawn — this feed carries transaction prices only, and a price history inferred from them would imply market data the filings do not contain.

Open-market purchase Open-market sale
2026-10-22 — Kaye Mark · sold 400 @ $434.00 2026-10-22 — Kaye Mark · sold 321 @ $435.25 2026-10-22 — Kaye Mark · sold 1,660 @ $436.20 2026-10-22 — Kaye Mark · sold 560 @ $437.07 2026-10-22 — Kaye Mark · sold 240 @ $438.22 2026-10-22 — Kaye Mark · sold 1,160 @ $439.25 2026-10-22 — Kaye Mark · sold 1,720 @ $440.44 2026-10-22 — Kaye Mark · sold 2,343 @ $441.34 2026-10-22 — Kaye Mark · sold 480 @ $442.61 2026-10-22 — Kaye Mark · sold 440 @ $443.81 2026-10-22 — Kaye Mark · sold 160 @ $444.85 2026-10-22 — Kaye Mark · sold 827 @ $446.05 2026-10-22 — Kaye Mark · sold 273 @ $447.19
2026-10-222026-10-22

Insider participation

One row per insider, one cell per reported transaction, shaded by value. Repeat buying and activity clustered in time are visible at a glance.

Kaye Mark EVP & CFO
Included with a free account

The analysis built on top of these filings

The filings above are public record and stay public here. What an account adds for $ELV is the reading of them — and for this company, that is what the list below says it is, no more.

  • Transaction timelineThe [{'transaction_date': '2026-10-22', 'insider_name': 'Kaye Mark', 'insider_title': 'EVP & CFO', 'transaction_type': 'Open-market sell', 'shares': 400.0, 'price': 434.0, 'value': 173600.0, 'is_buy': False}, {'transaction_date': '2026-10-22', 'insider_name': 'Kaye Mark', 'insider_title': 'EVP & CFO', 'transaction_type': 'Open-market sell', 'shares': 321.0, 'price': 435.25, 'value': 139715.25, 'is_buy': False}, {'transaction_date': '2026-10-22', 'insider_name': 'Kaye Mark', 'insider_title': 'EVP & CFO', 'transaction_type': 'Open-market sell', 'shares': 1660.0, 'price': 436.2, 'value': 724092.0, 'is_buy': False}, {'transaction_date': '2026-10-22', 'insider_name': 'Kaye Mark', 'insider_title': 'EVP & CFO', 'transaction_type': 'Open-market sell', 'shares': 560.0, 'price': 437.07, 'value': 244759.2, 'is_buy': False}, {'transaction_date': '2026-10-22', 'insider_name': 'Kaye Mark', 'insider_title': 'EVP & CFO', 'transaction_type': 'Open-market sell', 'shares': 240.0, 'price': 438.22, 'value': 105172.8, 'is_buy': False}, {'transaction_date': '2026-10-22', 'insider_name': 'Kaye Mark', 'insider_title': 'EVP & CFO', 'transaction_type': 'Open-market sell', 'shares': 1160.0, 'price': 439.25, 'value': 509530.0, 'is_buy': False}, {'transaction_date': '2026-10-22', 'insider_name': 'Kaye Mark', 'insider_title': 'EVP & CFO', 'transaction_type': 'Open-market sell', 'shares': 1720.0, 'price': 440.44, 'value': 757556.8, 'is_buy': False}, {'transaction_date': '2026-10-22', 'insider_name': 'Kaye Mark', 'insider_title': 'EVP & CFO', 'transaction_type': 'Open-market sell', 'shares': 2343.0, 'price': 441.34, 'value': 1034059.62, 'is_buy': False}, {'transaction_date': '2026-10-22', 'insider_name': 'Kaye Mark', 'insider_title': 'EVP & CFO', 'transaction_type': 'Open-market sell', 'shares': 480.0, 'price': 442.61, 'value': 212452.8, 'is_buy': False}, {'transaction_date': '2026-10-22', 'insider_name': 'Kaye Mark', 'insider_title': 'EVP & CFO', 'transaction_type': 'Open-market sell', 'shares': 440.0, 'price': 443.81, 'value': 195276.4, 'is_buy': False}, {'transaction_date': '2026-10-22', 'insider_name': 'Kaye Mark', 'insider_title': 'EVP & CFO', 'transaction_type': 'Open-market sell', 'shares': 160.0, 'price': 444.85, 'value': 71176.0, 'is_buy': False}, {'transaction_date': '2026-10-22', 'insider_name': 'Kaye Mark', 'insider_title': 'EVP & CFO', 'transaction_type': 'Open-market sell', 'shares': 827.0, 'price': 446.05, 'value': 368883.35, 'is_buy': False}, {'transaction_date': '2026-10-22', 'insider_name': 'Kaye Mark', 'insider_title': 'EVP & CFO', 'transaction_type': 'Open-market sell', 'shares': 273.0, 'price': 447.19, 'value': 122082.87, 'is_buy': False}] reported transactions plotted over the window rather than listed, so concentration is visible.

Not available for ELV today: no reported open-market purchases in this window, so there is no insider cost basis to compute; no research case — nothing here has cleared the scoring threshold. Both appear on this page on their own if that changes.

A free account opens all of it.

Not financial advice. This page reports public filings and past research output. It is not a recommendation to buy or sell, and no price target here is a prediction. Trade at your own risk.